Lyra Therapeutics Inc. Stock News

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.44 per share a year ago.

Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presente

Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incr

Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro

The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning

Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren

Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 t

Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatments. The company maintains a stable balance sheet

Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.

WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patien